-
Jul. 12, 2023Pharma DJ: SanegeneBio: an innovator for RNAi drugsPharmaDJ interviewed SanegeneBio's CEOMore
-
May 31, 2023Sanegene Announces Dosing of the First Subject in Phase I Trial of SGB-3403 Targeting PCSK9 for the Treatment of HypercholesterolemiaMore
-
Jan. 06, 2023SanegeneBio and Orbit Discovery Collaborate to Identify Targeting Peptides for RNAi DrugsMore
